Recent Company News

• 02:08 AM ET Apr 01, 2026
  

  Vivesto proposes 100:1 reverse share split and reduction of the share capital (SEK 0.08, 0.00)

• 04:35 AM ET Nov 20, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:05 AM ET Mar 13, 2026
  

  Vivesto announces first dogs have been dosed in ongoing pharmacokinetic and toxicology study with Cantrixil (SEK 0.08, 0.00)

• 11:52 AM ET Jan 23, 2026
  

  Vivesto announces outcome of rights issue: subscribed to 100% , company will receive ~ SEK 53.8M before issue costs (SEK 0.10, 0.00)

• 08:34 AM ET Jan 02, 2026
  

  Vivesto publishes information document regarding the previously announced ~SEK53.8M rights issue (SEK 0.11, 0.00)

• 02:05 AM ET Dec 16, 2025
  

  Vivesto engages Liberi Group to identify suitable potential international partners for its lead programs Paccal Vet and Cantrixil (SEK 0.13, 0.00)

• 02:40 AM ET Nov 20, 2025
  

  Vivesto announces a fully secured rights issue of ~SEK53.8M, subject to approval by an EGM; Subscription period will be in Jan-26 (SEK 0.24, 0.00)

• 09:18 AM ET Nov 07, 2025
  

  Vivesto announces positive interim results for Paccal Vet pilot study in dogs (SEK 0.27, +0.04)